NovaBay Operating Income vs Gross Profit Analysis

NBY Stock

USD 0.17 0.05 41.67%

NovaBay Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating NovaBay Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NovaBay Pharmaceuticals is a good investment. Please check the relationship between NovaBay Pharmaceuticals Operating Income and its Gross Profit accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

Operating Income vs Gross Profit

Operating Income vs Gross Profit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NovaBay Pharmaceuticals Operating Income account and Gross Profit. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between NovaBay Pharmaceuticals' Operating Income and Gross Profit is 0.4. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Gross Profit in the same time period over historical financial statements of NovaBay Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of NovaBay Pharmaceuticals' Operating Income and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of NovaBay Pharmaceuticals are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Operating Income i.e., NovaBay Pharmaceuticals' Operating Income and Gross Profit go up and down completely randomly.

Correlation Coefficient

0.4

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Operating Income

Operating Income is the amount of profit realized from NovaBay Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of NovaBay Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of NovaBay Pharmaceuticals minus its cost of goods sold. It is profit before NovaBay Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most indicators from NovaBay Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NovaBay Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.At this time, NovaBay Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 18.2 M in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	5.6M	7.8M	7.9M	8.1M
Total Revenue	8.4M	14.4M	14.7M	10.0M

Gross Profit Total Revenue

NovaBay Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Other Liab	Current Deferred Revenue	Non Current Liabilities Total	Short Long Term Debt Total	Short Term Debt
Total Assets		0.83	-0.37	0.1	0.34	0.45	0.16	0.17	0.33	-0.61	-0.25	-0.16	0.73	0.64	0.63	0.5	0.0	0.37	0.87	0.59	0.3	0.23	-0.11	0.12	-0.19	-0.05
Total Stockholder Equity	0.83		-0.11	0.02	0.13	-0.11	0.02	-0.2	0.28	-0.76	-0.04	-0.4	0.79	0.34	0.74	0.54	0.02	0.29	0.88	0.62	0.33	0.2	0.06	-0.21	-0.29	-0.24
Other Assets	-0.37	-0.11		0.13	0.05	-0.49	-0.49	-0.45	-0.23	0.25	-0.09	-0.56	-0.31	-0.02	-0.38	-0.33	-0.66	-0.15	-0.39	-0.3	-0.18	0.38	0.55	0.07	-0.07	-0.48
Common Stock Shares Outstanding	0.1	0.02	0.13		0.76	0.04	-0.5	0.23	0.45	0.48	-0.75	0.0	-0.2	0.23	-0.39	0.29	-0.17	0.56	-0.15	-0.17	0.73	0.79	-0.07	-0.2	-0.04	0.12
Other Stockholder Equity	0.34	0.13	0.05	0.76		0.34	-0.13	0.59	0.39	0.31	-0.99	0.04	-0.07	0.44	-0.34	0.33	-0.32	0.51	0.03	0.12	0.46	0.64	-0.06	-0.24	0.18	-0.03
Total Liab	0.45	-0.11	-0.49	0.04	0.34		0.31	0.63	0.12	0.06	-0.34	0.37	0.05	0.6	-0.03	0.05	-0.02	0.2	0.16	0.1	-0.06	0.03	-0.29	0.57	0.15	0.26
Other Current Liab	0.16	0.02	-0.49	-0.5	-0.13	0.31		0.44	-0.27	-0.45	0.14	0.32	0.36	-0.26	0.35	-0.15	0.31	-0.36	0.37	0.04	-0.34	-0.52	-0.22	-0.14	0.26	-0.04
Total Current Liabilities	0.17	-0.2	-0.45	0.23	0.59	0.63	0.44		0.32	0.24	-0.61	0.25	-0.06	0.09	-0.19	0.06	0.04	0.29	0.06	0.0	0.08	-0.08	-0.18	-0.19	0.65	0.35
Property Plant And Equipment Net	0.33	0.28	-0.23	0.45	0.39	0.12	-0.27	0.32		0.14	-0.37	-0.04	0.1	0.27	0.13	0.45	-0.13	0.95	0.21	0.38	0.75	0.44	-0.17	-0.19	0.02	0.45
Net Debt	-0.61	-0.76	0.25	0.48	0.31	0.06	-0.45	0.24	0.14		-0.39	0.22	-0.91	0.0	-0.93	-0.35	-0.29	0.21	-0.86	-0.49	0.19	0.27	0.16	0.08	0.24	0.12
Retained Earnings	-0.25	-0.04	-0.09	-0.75	-0.99	-0.34	0.14	-0.61	-0.37	-0.39		-0.06	0.16	-0.43	0.42	-0.29	0.35	-0.51	0.06	-0.08	-0.42	-0.63	0.05	0.21	-0.22	0.03
Accounts Payable	-0.16	-0.4	-0.56	0.0	0.04	0.37	0.32	0.25	-0.04	0.22	-0.06		-0.24	0.05	-0.23	0.18	0.48	0.03	-0.29	0.14	0.09	-0.04	-0.65	0.13	-0.22	0.24
Cash	0.73	0.79	-0.31	-0.2	-0.07	0.05	0.36	-0.06	0.1	-0.91	0.16	-0.24		0.05	0.92	0.45	0.19	0.0	0.91	0.49	0.01	-0.04	-0.32	-0.13	-0.25	0.14
Non Current Assets Total	0.64	0.34	-0.02	0.23	0.44	0.6	-0.26	0.09	0.27	0.0	-0.43	0.05	0.05		-0.03	0.34	-0.34	0.49	0.21	0.46	0.23	0.49	0.02	0.57	-0.29	-0.18
Cash And Short Term Investments	0.63	0.74	-0.38	-0.39	-0.34	-0.03	0.35	-0.19	0.13	-0.93	0.42	-0.23	0.92	-0.03		0.37	0.29	0.0	0.89	0.45	-0.01	-0.22	-0.27	-0.08	-0.25	0.16
Common Stock Total Equity	0.5	0.54	-0.33	0.29	0.33	0.05	-0.15	0.06	0.45	-0.35	-0.29	0.18	0.45	0.34	0.37		0.4	0.52	0.42	0.76	0.42	0.33	-0.48	-0.25	-0.3	0.24
Other Current Assets	0.0	0.02	-0.66	-0.17	-0.32	-0.02	0.31	0.04	-0.13	-0.29	0.35	0.48	0.19	-0.34	0.29	0.4		-0.19	0.18	0.19	0.04	-0.45	-0.38	-0.24	0.02	0.24
Property Plant And Equipment Gross	0.37	0.29	-0.15	0.56	0.51	0.2	-0.36	0.29	0.95	0.21	-0.51	0.03	0.0	0.49	0.0	0.52	-0.19		0.15	0.4	0.78	0.59	-0.12	-0.07	-0.05	0.28
Total Current Assets	0.87	0.88	-0.39	-0.15	0.03	0.16	0.37	0.06	0.21	-0.86	0.06	-0.29	0.91	0.21	0.89	0.42	0.18	0.15		0.51	0.15	-0.07	-0.1	-0.14	-0.08	-0.02
Common Stock	0.59	0.62	-0.3	-0.17	0.12	0.1	0.04	0.0	0.38	-0.49	-0.08	0.14	0.49	0.46	0.45	0.76	0.19	0.4	0.51		0.19	0.09	-0.28	-0.08	-0.31	0.02
Property Plant Equipment	0.3	0.33	-0.18	0.73	0.46	-0.06	-0.34	0.08	0.75	0.19	-0.42	0.09	0.01	0.23	-0.01	0.42	0.04	0.78	0.15	0.19		0.64	-0.08	-0.28	-0.22	0.1
Other Liab	0.23	0.2	0.38	0.79	0.64	0.03	-0.52	-0.08	0.44	0.27	-0.63	-0.04	-0.04	0.49	-0.22	0.33	-0.45	0.59	-0.07	0.09	0.64		-0.11	0.09	-0.46	-0.06
Current Deferred Revenue	-0.11	0.06	0.55	-0.07	-0.06	-0.29	-0.22	-0.18	-0.17	0.16	0.05	-0.65	-0.32	0.02	-0.27	-0.48	-0.38	-0.12	-0.1	-0.28	-0.08	-0.11		-0.01	0.41	-0.67
Non Current Liabilities Total	0.12	-0.21	0.07	-0.2	-0.24	0.57	-0.14	-0.19	-0.19	0.08	0.21	0.13	-0.13	0.57	-0.08	-0.25	-0.24	-0.07	-0.14	-0.08	-0.28	0.09	-0.01		-0.3	0.0
Short Long Term Debt Total	-0.19	-0.29	-0.07	-0.04	0.18	0.15	0.26	0.65	0.02	0.24	-0.22	-0.22	-0.25	-0.29	-0.25	-0.3	0.02	-0.05	-0.08	-0.31	-0.22	-0.46	0.41	-0.3		0.03
Short Term Debt	-0.05	-0.24	-0.48	0.12	-0.03	0.26	-0.04	0.35	0.45	0.12	0.03	0.24	0.14	-0.18	0.16	0.24	0.24	0.28	-0.02	0.02	0.1	-0.06	-0.67	0.0	0.03

Click cells to compare fundamentals

NovaBay Pharmaceuticals Account Relationship Matchups

NovaBay Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	11.2M	15.2M	24.0M	16.4M	9.0M	14.4M
Total Stockholder Equity	973K	12.3M	10.2M	10.6M	3.3M	5.3M
Other Assets	477K	912K	476K	489K	562.4K	461.6K
Common Stock Shares Outstanding	618.3K	1.0M	1.2M	1.6M	4.2M	4.4M
Liabilities And Stockholders Equity	11.2M	15.2M	24.0M	16.4M	9.0M	14.4M
Other Stockholder Equity	125.7M	148.0M	150.9M	165.1M	176.4M	185.2M
Total Liab	10.2M	2.9M	13.8M	5.8M	5.7M	7.1M
Other Current Liab	993K	1.4M	803K	917K	570K	541.5K
Total Current Liabilities	5.7M	2.8M	3.4M	4.3M	4.3M	4.1M
Property Plant And Equipment Net	1.4M	520K	604K	2.0M	1.4M	1.0M
Net Debt	(2.9M)	(11.4M)	(7.0M)	(3.3M)	(390K)	(409.5K)
Retained Earnings	(125.0M)	(136.1M)	(141.9M)	(158.2M)	(174.8M)	(166.1M)
Accounts Payable	331K	302K	1.0M	1.1M	1.1M	812.7K
Cash	6.9M	12.0M	7.5M	5.4M	3.1M	6.0M
Non Current Assets Total	1.8M	996K	10.8M	5.1M	1.9M	2.0M
Cash And Short Term Investments	6.9M	12.0M	7.5M	5.4M	3.1M	3.0M
Common Stock Total Equity	154K	171K	279K	418K	480.7K	263.6K
Other Current Assets	105K	102K	144K	113K	388K	271.6K
Property Plant And Equipment Gross	1.4M	520K	1.2M	2.6M	2.1M	1.1M
Total Current Assets	9.4M	14.2M	13.2M	11.3M	7.2M	9.5M
Accumulated Other Comprehensive Income	(243K)	(509K)	(560K)	(275K)	(247.5K)	(259.9K)
Common Stock	279K	418K	478K	652K	112K	106.4K
Property Plant Equipment	110K	520K	604K	2.0M	1.8M	1.8M
Other Liab	2.5M	560K	4.1M	10.1M	11.6M	12.2M
Current Deferred Revenue	822K	730K	1.3M	1.8M	946K	1.2M
Non Current Liabilities Total	4.6M	87K	10.4M	1.6M	1.4M	2.6M
Short Term Debt	3.5M	416K	305K	453K	1.6M	1.7M
Non Currrent Assets Other	77K	2K	476K	489K	21K	20.0K
Net Receivables	1.1M	1.1M	1.7M	2.0M	759K	721.1K
Net Tangible Assets	5.0M	973K	12.3M	(237K)	(213.3K)	(202.6K)
Retained Earnings Total Equity	(111.1M)	(115.0M)	(125.0M)	(136.1M)	(122.5M)	(116.3M)
Capital Surpluse	125.7M	148.0M	150.9M	165.1M	189.8M	118.8M
Inventory	492K	608K	3.2M	3.4M	2.9M	3.0M
Non Current Liabilities Other	198K	4.6M	561K	334K	300.6K	285.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

VWITX	Vanguard Intermediate Term Tax Exempt
VGSTX	Vanguard Star Fund
VFIAX	Vanguard 500 Index

When determining whether NovaBay Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NovaBay Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novabay Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novabay Pharmaceuticals Stock:

How To Invest In NovaBay

Details

Is NovaBay Stock a good investment?

Details

What is NovaBay Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

Note that the NovaBay Pharmaceuticals information on this page should be used as a complementary analysis to other NovaBay Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.

Complementary Tools for NovaBay Stock analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Commodity Directory Find actively traded commodities issued by global exchanges
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes

Is NovaBay Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NovaBay Pharmaceuticals. If investors know NovaBay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NovaBay Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.96)

Revenue Per Share

3.494

Quarterly Revenue Growth

0.023

Return On Assets

(0.25)

Return On Equity

(1.39)

The market value of NovaBay Pharmaceuticals is measured differently than its book value, which is the value of NovaBay that is recorded on the company's balance sheet. Investors also form their own opinion of NovaBay Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is NovaBay Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NovaBay Pharmaceuticals' market value can be influenced by many factors that don't directly affect NovaBay Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NovaBay Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if NovaBay Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NovaBay Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NovaBay Operating Income vs Gross Profit Analysis

Operating Income vs Gross Profit

Operating Income vs Gross Profit Correlation Analysis

Correlation Coefficient

Operating Income

Gross Profit

NovaBay Pharmaceuticals fundamental ratios Correlations

NovaBay Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NovaBay Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for NovaBay Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 0.95	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.92	Cash
Total Current Assets	+ 0.91	Cash
Total Current Assets	+ 0.89	Cash And Short Term Investments
Total Current Assets	+ 0.88	Total Stockholder Equity
Total Current Assets	+ 0.87	Total Assets

Retained Earnings	- 0.99	Other Stockholder Equity
Cash And Short Term Investments	- 0.93	Net Debt
Cash	- 0.91	Net Debt
Total Current Assets	- 0.86	Net Debt
Net Debt	- 0.76	Total Stockholder Equity
Retained Earnings	- 0.75	Common Stock Shares Outstanding